Plant-Based Edge ATB Therapeutics' ATBioFarm platform enables single-step, plant-based manufacturing of novel atbodies, offering potential speed, scalability, and cost advantages that are attractive to contract manufacturers and pharma partners seeking efficient biologics production.

Oncology Differentiation The proprietary atbody class targets hard-to-treat cancers with a novel mechanism of action aimed at broadening therapeutic windows and reducing resistance, presenting licensing or co-development opportunities for oncology-focused partners.

Investment Momentum Recent €54-57M Series A funding and a leadership change to CEO Mark Throsby signal growth readiness and external validation, creating openings for strategic alliances, co-development deals, and potential exits with investors and buyers.

EU Collaboration Potential Based in Wallonia, Belgium with a lean team, ATB Therapeutics is well positioned to engage European pharma players, academic partners, and EU-funded collaboration programs for early development and manufacturing partnerships.

Partnership Track Record A historical collaboration with iBio to produce bioengineered antibody-toxin fusions demonstrates willingness and capability to partner on manufacturing and technology transfer, signaling a favorable temperament for new BD deals.